Post-Exposure Prophylaxis: For Sexual Exposure in the LGBTQIA+ Community

Human immunodeficiency viruses (HIV) and, subsequently, acquired immune deficiency syndrome emphasize the significance of prevention and treatment, especially among vulnerable populations. Some subgroups of the LGBTQIA+ community, namely men who have sex with men (MSM) and transgender individuals, can be disproportionately affected by this disease. As the health care community recognizes this health concern, post-exposure prophylaxis has become important in preventing HIV spread. The current practices depend on two-pill approaches that combine emtricitabine/tenofovir with either dolutegravir or raltegravir. However, the introduction of the one-pill bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) improves the chances of receiving prophylactic treatment by people with serious renal health issues. The purpose of the clinical recommendation is to present MSM and transgender patients who might have contracted HIV with an alternative treatment of BIC/FTC/TAF that reduces renal side effects and requires a single pill a day.